Activated Charcoal Anemone Pulsatilla Antimony Tri
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Activated Charcoal Anemone Pulsatilla Antimony Tri
- Multi-Ingredient Homeopathic Preparation: Insufficient Data for Repurposing Evaluation
Multi-Ingredient Homeopathic Preparation: Insufficient Data for Repurposing Evaluation
One-Sentence Summary
This candidate consists of a 27-component homeopathic mixture (including Arsenicum Album, Lachesis Muta Venom, Nux Vomica, Sulfur, Mercury, and others), with no registered indication on record in any market queried. The TxGNN model returned no predicted indications for this entry, and no clinical trial or literature evidence is available to support any repurposing direction. This record cannot advance to a standard evaluation without fundamental data remediation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | None on record |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | Below L5 (no predictions, no studies) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
The TxGNN model operates by mapping a drug to a DrugBank node and traversing the knowledge graph to identify disease nodes with high repurposing probability. This pipeline requires:
- A resolvable DrugBank ID for the compound
- A single, unified chemical or biological entity (not a mixture of 27 ingredients)
- A known mechanism of action that can be encoded as graph edges
None of these prerequisites are met for this record. The “drug” submitted is a list of 27 separate substances — many of which are classical homeopathic dilutions (e.g., Arsenicum Album, Lachesis Muta Venom, Mercurius, Sulfur, Nux Vomica Seed) rather than a single pharmacological agent. Because the query string was passed as a concatenated INN list, no DrugBank match was found, and the knowledge graph could not anchor a prediction.
Additionally, homeopathic preparations as a class typically lack quantifiable pharmacokinetic or pharmacodynamic data, which further prevents standard MOA-based graph traversal.
US Market Information
No authorizations found. This compound has not been registered with the FDA under any NDA or homeopathic OTC monograph associated with this specific combination.
Safety Considerations
No structured safety data is available for this multi-ingredient combination. Please refer to individual ingredient package inserts and relevant pharmacopoeia monographs for component-level warnings. Note that several individual ingredients (Arsenic Trioxide, Mercury, Lachesis Muta Venom, Strychnos Nux-Vomica Seed) carry well-established toxicological profiles at pharmacological doses.
Conclusion and Next Steps
Decision: Hold
Rationale: This record cannot be evaluated as a drug repurposing candidate because it lacks a resolvable drug identity, a DrugBank ID, any regulatory approval, and any TxGNN prediction output. The compound structure — a 27-ingredient homeopathic mixture — is incompatible with the current single-entity TxGNN pipeline.
To proceed, the following is needed:
- Clarify evaluation intent: Determine whether the goal is to evaluate one specific active ingredient from this list (e.g., Arsenic Trioxide, which has an approved oncology indication) or the mixture as a whole.
- Decompose the record: If evaluating individual components, split into separate candidates and resubmit each with its own DrugBank ID and INN.
- Obtain a DrugBank ID: At minimum one DrugBank-resolvable entity is required to trigger graph-based prediction.
- Resolve regulatory origin: Identify which country registered or submitted this combination, and retrieve the corresponding product monograph or indication text.
- MOA documentation: Until a specific active entity is isolated, mechanism-of-action analysis cannot proceed.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.